1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Summary: The fiscal year 2026 (FY26) Spinal Cord Injury Research Program (SCIRP) Clinical Translation Research Award (CTRA) supports high-impact, new, or emerging clinical research that requires additional preliminary studies, such as feasibility, pilot, or optimization, to prepare for future larger-scale clinical trials or implementation. Primary objectives of this mechanism include:• Accelerating the translation of current and emerging techniques or interventions into clinical use by addressing specific barrier(s) to clinical success for the purpose of de-risking or informing the design of definitive trials.• Identifying the most effective diagnosis, treatment and rehabilitation options to support critical decision-making for patients, clinicians, care partners and policymakers.Distinctive Features:• This funding opportunity contains an Early-Career Partnership Option, which allows for two principal investigators (PIs). If this option is selected, at least one of the named PIs must be an early-career investigator. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn.• Applications to this funding opportunity must name at least two spinal cord injury (SCI) community partners who will provide advice and consultation throughout the planning and implementation of the research project.
Funding Opportunity Number: HT942526SCIRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $6.1M total program funding.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Eligible applicants: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility. Confirm the full requirements in the official notice before applying.
The current listing shows $6.1M total program funding. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for DoW Spinal Cord Injury, Clinical Translation Research Award are due November 12, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Yes — DoW Spinal Cord Injury, Clinical Translation Research Award is offered by Dept. of the Army -- USAMRAA and this listing comes from Grants.gov, an official U.S. federal source. Federal applications generally require registrations (for example SAM.gov or an agency submission portal), so allow extra lead time.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation. This award supports impactful, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with Duchenne muscular dystrophy (DMD) in the near term. Applications should include a well-formulated, testable hypothesis based on strong scientific rationale. The DMDRP strongly encourages research projects investigating therapies designed to demonstrate efficacy cross the life span, including infants, toddlers and nonambulatory individuals.Distinctive Features: The FY26 DMDRP IDA mechanism offers three eligibility career categories:• The Established Investigator category is for independent investigators at all academic levels, or equivalent• The New Investigator – Early-Stage category is for independent investigators early in their careers (i.e., within 10 years of their first faculty appointment or equivalent). Applicants in this category will be reviewed separately from Established Investigators.• The New Investigator – Transitioning category is for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy who are seeking to transition to a career in DMD, thereby bringing their expertise to the field. Applicants in this category will be reviewed separately from Established Investigators.Preliminary data relevant to DMD that supports the feasibility of the research hypotheses and research approaches are required for all applications. Clinical trials or clinical trial aims are not allowed. Funding Opportunity Number: HT942526DMDRPIDA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $2.5M total program funding.
Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Clinical/Translational Research Award (CTRA) supports advanced translational research to accelerate promising ideas in Duchenne muscular dystrophy (DMD) research toward clinical applications. Research must address at least one of the FY26 CTRA Focus Areas. Research projects investigating therapies that will be efficacious across the life span are strongly encouraged.Distinctive Features: The FY26 CTRA offers two funding levels:• Funding Level 1 to support smaller, less complex preclinical and/or clinical research.• Funding Level 2 to support larger, more complex preclinical and/or clinical research.The FY26 CTRA also offers a Partnering PI Option (PPIO) to support meaningful and productive partnerships between two investigators collaborating on the proposed research project. The PPIO has two eligibility categories:• Early-Career Partnering PI category for an independent, early-career investigator within 10 years of their first faculty appointment (or equivalent) by the time of application submission.• Established Interdisciplinary Partnering PI for independent investigators at all academic levels, or equivalent, in an area other than muscular dystrophy, seeking to transition to a career in DMD, thereby bringing their expertise to the field.Preliminary data are required for all applications. Pilot clinical trials and clinical trial readiness studies to better inform development of drugs, devices, and other interventions are allowed. Funding Opportunity Number: HT942526DMDRPCTRA. Assistance Listing: 12.420. Funding Instrument: G. Category: ST. Award Amount: $8.5M total program funding.
DoW Duchenne Muscular Dystrophy, Idea Development Award is sponsored by Dept. of the Army -- USAMRAA. Summary: The fiscal year 2026 (FY26) Duchenne Muscular Dystrophy Research Program (DMDRP) Idea Development Award (IDA) promotes new ideas that are still in the early stages of development and have the potential to yield impactful data and new avenues of investigation.
Craig H. Neilsen Foundation Allied Health Professional Research Award of ASIA is sponsored by Craig H. Neilsen Foundation (administered by ASIA). This award encourages allied health professionals at the Master's or Clinical Doctorate level with an interest in research to pursue a career as researchers in the field of spinal cord injury. The recipient will be mentored by an experienced researcher.
Craig H. Neilsen Foundation Allied Health Professional Research Award of ASIA is sponsored by Craig H. Neilsen Foundation (administered by ASIA - American Spinal Injury Association). This award encourages allied health professionals at the Master's or Clinical Doctorate level, particularly those with limited research experience, to pursue a career as researchers in the field of spinal cord injury (SCI).
After SBIR reauthorization, the U.S. Army released five new small-business topics under Army FUZE — Ka-Band metamaterial radar, a Li-ion 6T battery open topic, in-transit-visibility blockchain, modular UAS payloads, and the xTech|Phantum prize competition. Awards run from $150K to $300K per Phase I. But the bigger story is the Army's shift from funding parts to funding whole systems. Here is what each topic funds and how to compete.
Read articleDARPA transferred its first autonomous-ready H-60Mx Black Hawk to the Army on March 20, capping a decade of ALIAS research. Now the same technology underpins an SBIR XL opportunity for small businesses building wildfire autonomy.
Read article